Johnson & Johnson (JNJ): FY25 Q3 earnings call, Oct 14, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Oct 14, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
5 matches for “Ottava”; 5 quoted, at least 25 words apart.
…of our latest innovations. We also continue to make positive progress with Ottava as we anticipate FDA de novo submission in early 2026. And now…
…MedTech, we continue to make progress with our clinical trial for our Ottava robotic surgical system. In our cardiovascular portfolio, we are planning regulatory submissions…
…intraocular lens in The U.S., as well as regulatory submission for the Ottava robotic surgical system. Again, while early, I like the way 2026 is…
…file with the FDA in the first half of the year our Ottava soft tissue robotic system. We are also determined to be a major…
…robotic surgery, where we are focusing on being able to submit our Ottava soft tissue robotic system to the FDA in 2026. We'll continue to…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-10-14:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-10-14:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP